X T L Biopharmaceuticals Ltd (XTLB) FinancialsXTLBX T L Biopharmaceuticals Ltd

X T L Biopharmaceuticals Ltd (XTLB) generates its revenue primarily from Operating Segment / Medical Devices, which accounts for -205.2% of total sales, equivalent to $-589.00K. Understanding this concentration is critical for investors evaluating how XTLB navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, X T L Biopharmaceuticals Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -29.30%, provide a clear picture of how effectively XTLB converts its operational activities into shareholder value.

In the context of the broader market, XTLB competes directly with industry leaders such as CVRX and DRIO. With a market capitalization of $3.81M, it holds a significant position in the sector. When comparing efficiency, XTLB's gross margin of N/A stands against CVRX's 87.39% and DRIO's 61.66%. Such benchmarking helps identify whether X T L Biopharmaceuticals Ltd is trading at a premium or discount relative to its financial performance.

XTLB reported total revenue of $289,000 for both Q4 2024 and Q1 2025, but it has a net income of -$255,000 for Q1 2025, indicating ongoing financial struggles. The gross margin remains at 0.00%, showing no profitability from sales.